Please Wait
Applying Filters...
menu
    • menu
    Abbvie Contract Manufacturing-PSE
    News
    ImmunoGen`s Biologics Elahere Receives Suppl Approval in US

    14 Jul 2025

    // FDA

    Zydus, Gates Foundation To Develop Shigellosis-Typhoid Vaccine

    04 Mar 2025

    // INDPHARMAPOST

    Valneva Reports Positive Phase 2 Chikungunya Vaccine Results

    22 Jan 2025

    // GLOBENEWSWIRE

    Data Compilation
    #PharmaFlow

    Immunogen

    Contact Supplier

    Website

    SCOPE Summit

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/fda-opoe
    Menu

    Immunogen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital content

    Explore the latest content creation from this company

    NEWS #PharmaBuzz

    read-more
    read-more
    ImmunoGen`s Biologics Elahere Receives Suppl Approval in US
    ImmunoGen`s Biologics Elahere Receives Suppl Approval in US

    14 Jul 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761310

    FDA
    14 Jul 2025
    Share Share
    Zydus, Gates Foundation To Develop Shigellosis-Typhoid Vaccine
    Zydus, Gates Foundation To Develop Shigellosis-Typhoid Vaccine

    04 Mar 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/zydus-and-gates-foundation-to-develop-worlds-first-combination-vaccine-to-offer-protection-against-shigellosis-and-typhoid-16850

    INDPHARMAPOST
    04 Mar 2025
    Share Share
    Valneva Reports Positive Phase 2 Chikungunya Vaccine Results
    Valneva Reports Positive Phase 2 Chikungunya Vaccine Results

    22 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/22/3013729/0/en/Valneva-Reports-Positive-Phase-2-Results-in-Children-for-its-Chikungunya-Vaccine-and-Announces-Phase-3-Dose-Decision.html

    GLOBENEWSWIRE
    22 Jan 2025
    Share Share
    PopVax Wins $2M BARDA Prize For Flu Vaccine Using Microarray Patch
    PopVax Wins $2M BARDA Prize For Flu Vaccine Using Microarray Patch

    13 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250113384141/en

    BUSINESSWIRE
    13 Jan 2025
    Share Share
    Nature Highlights Stratis® DNA Vaccine For Hantaviruses
    Nature Highlights Stratis® DNA Vaccine For Hantaviruses

    10 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241210862815/en

    BUSINESSWIRE
    10 Dec 2024
    Share Share
    Vaxcyte Starts Phase 2 Study of VAX-31 in Infants
    Vaxcyte Starts Phase 2 Study of VAX-31 in Infants

    03 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/03/2990544/0/en/Vaxcyte-Initiates-Phase-2-Study-Evaluating-VAX-31-for-the-Prevention-of-Invasive-Pneumococcal-Disease-in-Infants.html

    GLOBENEWSWIRE
    03 Dec 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.